Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Glaucoma 9
2.1.2 Age-Related Macular Degeneration 10
2.1.3 Diabetic Retinopathy 10
2.1.4 Diabetic Macular Edema 10
2.1.5 Dry Eye Syndrome 11
2.2 Symptoms 11
2.3 Diagnosis 13
2.4 Etiology and Pathophysiology 13
2.4.1 Etiology 13
2.4.2 Pathophysiology 15
2.5 Co-morbidities and Complications 18
2.6 Prognosis 19
2.6.1 Glaucoma 19
2.6.2 Age-Related Macular Degeneration 20
2.6.3 Diabetic Retinopathy and Diabetic Macular Edema 20
2.6.4 Dry Eye Syndrome 20
2.7 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 21
2.7.1 Glaucoma 21
2.7.2 Age-Related Macular Degeneration 22
2.7.3 Diabetic Macular Edema 23
2.7.4 Diabetic Retinopathy 24
2.7.5 Dry Eye Syndrome 25
2.8 Treatment 26
3 Key Marketed Products 29
3.1 Overview 29
3.2 Lucentis (ranibizumab) 29
3.3 Eylea (aflibercept) 30
3.4 Avastin (bevacizumab) 32
3.5 Restasis (cyclosporine) 33
3.6 Alphagan (brimonidine tartrate) 35
3.7 Lumigan (bimatoprost) 36
3.8 Xalatan (latanoprost) 37
3.9 Conclusion 38
4 Pipeline Landscape Assessment 39
4.1 Overview 39
4.2 Pipeline Development Landscape 39
4.3 Molecular Targets in the Pipeline 41
4.4 Clinical Trials 43
4.4.1 Failure Rate 43
4.4.2 Clinical Trial Duration 47
4.4.3 Clinical Trial Size 51
4.4.4 Aggregate Clinical Program Size 54
4.4.5 Assessment of Key Pipeline Products 58
4.4.6 Conclusion 64
5 Multi-Scenario Market Forecast to 2023 65
5.1 Overall Market Size 65
5.2 Generic Penetration 69
5.2.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) 70
5.2.2 Antihistamines (Histamine H1 Receptor) 71
5.2.3 Anti-inflammatory Agents (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) 71
5.2.4 IOP Modulators (Prostaglandins, Beta Blockers and the Rho Kinase Signaling Pathway) 72
6 Company Analysis and Positioning 74
6.1 Revenue and Market Share Analysis by Company 75
6.1.1 Novartis – Can the Approval of Fovista and Brolucizumab Offset Revenue Lost Following Patent Expirations? 79
6.1.2 Regeneron – Will Regeneron be Able to Retain its Position in the Ophthalmology Market across the Forecast Period with Eylea Alone? 81
6.1.3 Roche – To What Extent Will Pipeline Product Approvals Offset the Patent Expiries of Lucentis and Avastin? 83
6.1.4 Bayer – Can Bayer Retain its Position in the Ophthalmology Market Given its Small Product Portfolio and Ophthalmology Pipeline? 85
6.1.5 Allergan – How Will Declining Revenue from Restasis Affect Allergan’s Overall Position within the Ophthalmology Therapy Area? 86
6.1.6 Shire – How Will Anticipated New Approvals Perform Across the Forecast Period? 87
6.1.7 Mallinckrodt – Will its Small Ophthalmology Portfolio and Limited Pipeline be Sufficient to Maintain the Position of Mallinckrodt in the Market? 88
6.1.8 Santen – Will Santen Continue to Rely on Ophthalmology Therapy Area for the Majority of its Company Revenue? 89
6.1.9 Aerie – Will Aerie be Able to Successfully Enter the Market with Two New Approvals? 91
6.2 Company Landscape 92
6.3 Marketed and Pipeline Portfolio Analysis 93
7 Strategic Consolidations 95
7.1 Licensing Deals 95
7.1.1 Deals by Region, Year and Value 95
7.1.2 Deals by Stage of Development and Value 97
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 98
7.1.4 Table for Licensing Deals Valued Above $100m 100
7.2 Co-development Deals 106
7.2.1 Deals by Region, Year and Value 106
7.2.2 Deals by Stage of Development and Value 107
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 108
7.2.4 Table for Co-development Deals Valued Above $100m 110
8 Appendix 113
8.1 References 113
8.2 Figures of All Clinical Stage Pipeline Products 121
8.3 Abbreviations 129
8.4 Disease List 130
8.5 Methodology 130
8.5.1 Coverage 130
8.5.2 Secondary Research 130
8.5.3 Market Size and Revenue Forecasts 131
8.5.4 Pipeline Analysis 131
8.5.5 Competitive Landscape 132
8.6 Contact Us 132
8.7 Disclaimer 132